X-linked adrenoleukodystrophy
Última atualização 26 Oct 2022
Atende aos diretrizes editoriais
- BaixarBaixar
- Compartilhar
- Language
- Discussão
- Ask Patient
- Versão em Áudio
- Adicionar às fontes preferidas no Google
X-linked adrenoleukodystrophy is a genetic disorder that mainly affects the nervous system and the adrenal glands, which are located on top of each kidney. In this disorder, the fatty covering (myelin) that insulates nerves in the brain and spinal cord tends to deteriorate (a condition called demyelination). The loss of myelin reduces the ability of the nerves to relay information to the brain. In addition, damage to the outer layer of the adrenal glands (adrenal cortex) causes a shortage of certain hormones (adrenocortical insufficiency). Adrenocortical insufficiency may cause weakness, weight loss, skin changes, vomiting, and coma.
Escolhas de vídeos para Condições genéticasBiblioteca de vídeos
Descrição
X-linked adrenoleukodystrophy is a genetic disorder that mainly affects the nervous system and the adrenal glands, which are located on top of each kidney. In this disorder, the fatty covering (myelin) that insulates nerves in the brain and spinal cord tends to deteriorate (a condition called demyelination). The loss of myelin reduces the ability of the nerves to relay information to the brain. In addition, damage to the outer layer of the adrenal glands (adrenal cortex) causes a shortage of certain hormones (adrenocortical insufficiency). Adrenocortical insufficiency may cause weakness, weight loss, skin changes, vomiting, and coma.
There are four distinct types of X-linked adrenoleukodystrophy: a childhood cerebral form, an adrenomyeloneuropathy type, an adrenal insufficiency only form, and a type called asymptomatic.
The childhood cerebral form of X-linked adrenoleukodystrophy typically occurs in boys. Girls are rarely affected with this type. If not treated, affected boys experience learning and behavioural problems that usually begin between the ages of 4 and 10. Over time the symptoms can worsen, and children may have difficulty reading, writing, understanding speech, and comprehending written material. Additional signs and symptoms of the cerebral form include aggressive behaviour, vision problems, difficulty swallowing, poor coordination, and impaired adrenal gland function. The rate at which this disorder progresses is variable but can be extremely rapid, often leading to total disability within a few years. The life expectancy of individuals with this type depends on whether early diagnosis and treatment are available. Without treatment, individuals with the cerebral form of X-linked adrenoleukodystrophy usually survive only a few years after symptoms begin.
Signs and symptoms of the adrenomyeloneuropathy type appear between early adulthood and middle age. Affected individuals develop progressive stiffness and weakness in their legs (paraparesis), experience urinary and genital tract disorders, and often show changes in behaviour and intellectual function. Most people with the adrenomyeloneuropathy type also have adrenocortical insufficiency. Some severely affected individuals develop cerebral X-linked adrenoleukodystrophy.
People with X-linked adrenoleukodystrophy whose only symptom is adrenocortical insufficiency are said to have the adrenal insufficiency only form. In these individuals, adrenocortical insufficiency can begin anytime between the first year of life and adulthood. However, most affected individuals develop the additional features of cerebral X-linked adrenoleukodystrophy in childhood or the adrenomyeloneuropathy type by the time they reach middle age. The life expectancy of individuals with the adrenal insufficiency form depends on the severity of the signs and symptoms, but typically this is the mildest of the three types.
Children with the asymptomatic form do not appear to have any symptoms of X-linked adrenoleukodystrophy, but medical testing may show brain or biochemical abnormalities. Some individuals with the asymptomatic form may develop features of other types of X-linked adrenoleukodystrophy later in life.
Rarely, individuals with X-linked adrenoleukodystrophy develop multiple features of the disorder in adolescence or early adulthood. In addition to adrenocortical insufficiency, these individuals usually have psychiatric disorders and a loss of intellectual function (dementia). It is unclear whether these individuals have a distinct form of the condition or a variation of one of the previously described types.
For reasons that are unclear, different forms of X-linked adrenoleukodystrophy can be seen in affected individuals within the same family.
Padrões de herança
The source lists the following possible inheritance patterns: X-linked. More than one pattern can apply in different cases.
Related genes
Other names
X-ALD
Related patient information and medicines

Patient information leaflet
Distúrbios de armazenamento de glicogênio
Glycogen storage disorders are rare. It is estimated that about one baby in every 20,000 to 40,000 babies born has a glycogen storage disorder. Autosomal recessive pattern of inheritance autosomal recessive pattern of inheritance Someone can be a carrier for a glycogen storage disorder. X-linked inheritance pattern x-linked pattern of inheritance.

Patient information leaflet
Distrofia muscular de Duchenne
Duchenne muscular dystrophy is a condition which causes progressive muscle weakness. Duchenne muscular dystrophy (DMD) is an inherited (genetic) condition which affects muscle strength and function. For a woman who carries the DMD gene, there is a 1 in 2 chance that her sons will have DMD, and a 1 in 2 chance that her daughters will carry the.
%20and%20Matcha%20together%3F/og.png)
Patient information leaflet
Posso tomar Certican (Everolimus) e Matcha juntos?
Drinking matcha tea while taking Certican (everolimus) may increase the levels of the medication in your bloodstream. This could lead to an increased risk of side effects, such as mouth ulcers, infections, or kidney problems. Why this happens Certican is broken down in the body by a specific enzyme (CYP3A4) and a transport protein.

Patient information leaflet
Hemofilia
Haemophilia is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platelets to form a clot. When you injure yourself the clot stops you bleeding. Haemophilia is a condition where there is a deficiency of clotting factors, so people with this condition usually have.

Patient information leaflet
Acesso simples e seguro ao seu registro de GP do NHS
Patient.info has partnered with ORB Connect - a UK, clinician-led, secure platform - to help you see and download your NHS GP records clearly and in one place. Why we’ve partnered with ORB We’ve teamed up with ORB - a secure, clinician-led UK service - to make reading and downloading your GP records easier than ever. ...protectionThe NHS App is a.

Patient information leaflet
Causas do câncer
Certain risk factors are known para increase the chance that one or more of your cells will become abnormal and lead to cancer. How does cancer start. The body is made up from millions of tiny cells. Different parts of the body such as organs, bones, muscles, skin and blood are made up from different specialised cells. Most cells have a centre.
Leitura adicional e referências
- X-linked adrenoleukodystrophy; MedlinePlus, National Library of Medicine.
- Berger J, Gartner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta. 2006 Dec;1763(12):1721-32. doi: 10.1016/j.bbamcr.2006.07.010. Epub 2006 Jul 26.
- Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr. 2005 Apr;146(4):528-32. doi: 10.1016/j.jpeds.2004.10.067.
- Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, Poll-The BT. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012 Aug 13;7:51. doi: 10.1186/1750-1172-7-51.
- Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012 Sep;1822(9):1465-74. doi: 10.1016/j.bbadis.2012.03.012. Epub 2012 Mar 28.
- Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, Cutting GR, Wanders RJ, Moser HW. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat. 2001 Dec;18(6):499-515. doi: 10.1002/humu.1227.
- Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol. 2007 Mar;3(3):140-51. doi: 10.1038/ncpneuro0421.
- Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB, Xu J, Jones RO, Loes DJ, Melhem ER, Dubey P, Bezman L, Brereton NH, Odone A. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol. 2005 Jul;62(7):1073-80. doi: 10.1001/archneur.62.7.1073.
- Tran C, Patel J, Stacy H, Mamak EG, Faghfoury H, Raiman J, Clarke JTR, Blaser S, Mercimek-Mahmutoglu S. Long-term outcome of patients with X-linked adrenoleukodystrophy: A retrospective cohort study. Eur J Paediatr Neurol. 2017 Jul;21(4):600-609. doi: 10.1016/j.ejpn.2017.02.006. Epub 2017 Feb 21.
Compartilhe seus pensamentos ou experiências com outros em nosso comunidades de pacientes.
Inscreva-se no boletim informativo do Patient
Sua dose semanal de conselhos de saúde claros e confiáveis - escritos para ajudá-lo a se sentir informado, confiante e no controle.
Ao se inscrever, você aceita nossos Política de Privacidade. Você pode cancelar a inscrição a qualquer momento. Nunca vendemos seus dados.

